Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enliven Therapeutics, Inc.IMRA · Entity 4024 | CFO & COO | February 22, 2023 | February 23, 2023 |
| POINT Biopharma Global Inc.TXAC · Entity 95793 | Director | July 07, 2020 | July 08, 2020 |
| Upstream Bio, Inc.UPB · Entity 5743 | CFO and COO | September 16, 2026 | September 17, 2026 |
| X4 Pharmaceuticals, IncASNS · Entity 5638 | Director · President, CEO and CFO | November 27, 2018 | November 29, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enliven Therapeutics, Inc.
Report date February 22, 2023 · Filed February 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,610 |
Reported balance
After 2023-02-22 transaction · row 1
1 source rowRow 1 · 2023-02-22 · Sale · Disposed 9,856 · Balance 27,610 F1: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units.
POINT Biopharma Global Inc.
Report date July 07, 2020 · Filed July 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-07-07 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Upstream Bio, Inc.
Report date September 16, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,942 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 853 · Balance 27,942 F1: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
X4 Pharmaceuticals, Inc
Report date November 27, 2018 · Filed November 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 250,000 |
Reported balance
After 2018-11-27 transaction · row 1
1 source rowRow 1 · 2018-11-27 · Grant · Acquired 250,000 · Balance 250,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 17, 2026 20:05 UTC | Upstream Bio, Inc. UPB · Entity 5743 | SaleCommon Stock | 853 | $5.49 | $4,682.97 |
DisclosureSEC source: 0001193125-26-394322 · ownership.xml · nonDerivative · entry 1 GRAY MICHAEL · CIK 0001271411 · CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,942 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 20:05 UTC | Upstream Bio, Inc. UPB · Entity 5743 | SaleCommon Stock | 853 | $6.10 | $5,203.30 |
DisclosureSEC source: 0001193125-26-274126 · ownership.xml · nonDerivative · entry 1 GRAY MICHAEL · CIK 0001271411 · CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,795 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:03 UTC | Upstream Bio, Inc. UPB · Entity 5743 | SaleCommon Stock | 852 | $9.29 | $7,915.08 |
DisclosureSEC source: 0001193125-26-111138 · ownership.xml · nonDerivative · entry 1 GRAY MICHAEL · CIK 0001271411 · CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,648 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:15 UTC | Upstream Bio, Inc. UPB · Entity 5743 | GrantStock Option (Right to Buy) · Derivative | 91,500 | $0.00 Strike: $27.07 | $0.00 |
DisclosureSEC source: 0001193125-26-004758 · ownership.xml · derivative · entry 2 GRAY MICHAEL · CIK 0001271411 · CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,500 Underlying: Common Stock · 91,500 shares Expires 2036-01-01 F2 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:15 UTC | Upstream Bio, Inc. UPB · Entity 5743 | GrantCommon Stock | 30,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-004758 · ownership.xml · nonDerivative · entry 1 GRAY MICHAEL · CIK 0001271411 · CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,500 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2024 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting. The RSUs shall vest in sixteen equal quarterly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 22:31 UTC | Upstream Bio, Inc. UPB · Entity 5743 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $8.53 | $0.00 |
DisclosureSEC source: 0000950170-25-016469 · ownership.xml · derivative · entry 1 GRAY MICHAEL · CIK 0001271411 · CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 22, 2023 Filed Feb 23, 2023 01:26 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | SaleCommon Stock | 9,856 | $4.67 | $46,027.52 |
DisclosureSEC source: 0001209191-23-012016 · doc4.xml · nonDerivative · entry 1 GRAY MICHAEL · CIK 0001271411 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,610 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 23:26 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | SaleCommon Stock | 3,596 | $3.92 | $14,096.32 |
DisclosureSEC source: 0001209191-23-005996 · doc4.xml · nonDerivative · entry 1 GRAY MICHAEL · CIK 0001271411 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,466 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:38 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Option (right to buy) · Derivative | 39,350 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001209191-22-005926 · doc4.xml · derivative · entry 2 GRAY MICHAEL · CIK 0001271411 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,350 Underlying: Common Stock · 39,350 shares Expires 2032-01-27 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:38 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantCommon Stock | 39,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005926 · doc4.xml · nonDerivative · entry 1 GRAY MICHAEL · CIK 0001271411 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,312 F1 · shares: The shares underlying the restricted stock unit vest over four years, with 25% of the shares vesting in equal annual installments until the fourth anniversary of the grant date. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:14 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Option (right to buy) · Derivative | 60,800 | $0.00 Strike: $13.83 | $0.00 |
DisclosureSEC source: 0001209191-21-005874 · doc4.xml · derivative · entry 2 GRAY MICHAEL · CIK 0001271411 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,800 Underlying: Common Stock · 60,800 shares Expires 2031-01-25 F1 · derivative.exercise_date: The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:26 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,250 | $0.00 Strike: $4.92 | $0.00 |
DisclosureSEC source: 0001209191-20-063476 · doc4.xml · derivative · entry 3 GRAY MICHAEL · CIK 0001271411 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,059 Underlying: Common Stock · 1,250 shares Expires 2029-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on May 16, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on April 8, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:26 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | SaleCommon Stock | 1,250 | $25.00 | $31,250.00 |
DisclosureSEC source: 0001209191-20-063476 · doc4.xml · nonDerivative · entry 2 GRAY MICHAEL · CIK 0001271411 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Mr. Gray's trading plan under Rule 10b5-1. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:26 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | Exercise / conversionCommon Stock | 1,250 | $4.92 | $6,150.00 |
DisclosureSEC source: 0001209191-20-063476 · doc4.xml · nonDerivative · entry 1 GRAY MICHAEL · CIK 0001271411 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 02:50 UTC | X4 Pharmaceuticals, Inc ASNS · Entity 5638 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-029784 · doc4.xml · nonDerivative · entry 1 GRAY MICHAEL · CIK 0001271411 · Director · President, CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 21:39 UTC | X4 Pharmaceuticals, Inc ASNS · Entity 5638 | GrantStock option (right to buy) · Derivative | 110,000 | $0.00 Strike: $17.34 | $0.00 |
DisclosureSEC source: 0001209191-18-018523 · doc4.xml · derivative · entry 1 GRAY MICHAEL · CIK 0001271411 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2028-03-06 F1 · derivative.exercise_date: This option becomes exercisable as to 25% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the fourth anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.